Frontotemporal dementia

Frontotemporal dementia
Name	Frontotemporal dementia
Field	Neurology
Symptoms	Behavioral change; language impairment; executive dysfunction
Onset	Middle age
Causes	Neurodegeneration; genetic mutations; protein aggregation
Diagnosis	Clinical assessment; neuroimaging; genetic testing
Treatment	Symptomatic management; supportive care
Frequency	Variable; second most common early-onset dementia

Frontotemporal dementia is a group of neurodegenerative disorders characterized by progressive deterioration of behavior, language, or executive function. Patients often present in midlife with changes that overlap with psychiatric syndromes, neurodegenerative disorders, and movement disorders, leading to diagnostic challenges in clinical settings such as memory clinics, neurology units, and psychiatric services. Prominent research centers, funding agencies, and advocacy organizations have advanced understanding through cohort studies, clinical trials, and genetic registries.

Signs and symptoms

Behavioral variants typically manifest with disinhibition, apathy, compulsivity, or loss of empathy, producing presentations that may be referred to specialists in psychiatric services, geriatric psychiatry, and neuropsychology at centers like Mayo Clinic (Rochester, Minnesota), Massachusetts General Hospital, and University College London. Language-predominant syndromes include progressive nonfluent aphasia and semantic impairment, leading to referrals to speech and language pathology units affiliated with institutions such as Johns Hopkins Hospital, Mount Sinai Hospital (Manhattan), and University of California, San Francisco. Motor features sometimes overlap with parkinsonian disorders and motor neuron disease, prompting assessment by movement disorders clinics linked to National Hospital for Neurology and Neurosurgery, Royal London Hospital, and Toronto Western Hospital. Neuropsychiatric manifestations often trigger involvement of multidisciplinary teams that include specialists from Stanford Hospital, Massachusetts Eye and Ear, and Cleveland Clinic.

Causes and pathophysiology

Pathology involves selective degeneration of frontal and temporal lobes associated with abnormal accumulation of proteins such as tau, TDP-43, or FUS, findings investigated in neuropathology units at Cambridge University Hospitals, Karolinska Institutet, and University of California, San Diego. Genetic causes include mutations in genes such as MAPT, GRN, and C9orf72 uncovered by consortia and research groups at Wellcome Trust Sanger Institute, Broad Institute, and European Molecular Biology Laboratory. Cellular mechanisms studied using models from laboratories at Max Planck Society, Howard Hughes Medical Institute, and Cold Spring Harbor Laboratory implicate synaptic dysfunction, impaired proteostasis, and neuroinflammation, topics explored in academic programs at Harvard University, Yale University, and University of Oxford. Environmental and modifier factors have been examined in longitudinal cohorts coordinated by organizations such as National Institutes of Health, European Union, and Michael J. Fox Foundation.

Diagnosis

Diagnosis is clinical and multimodal, integrating history, cognitive testing, neuroimaging, and genetic testing coordinated by memory clinics at institutions like King's College Hospital, Karolinska University Hospital, and John Radcliffe Hospital. Structural MRI and FDG-PET often demonstrate frontotemporal atrophy or hypometabolism evaluated in imaging centers at Stanford University Medical Center, UCSF Medical Center, and Imperial College Healthcare NHS Trust. Biomarker research including cerebrospinal fluid and plasma assays measured in laboratories at Scripps Research, National Institute on Aging, and Institut Pasteur aims to distinguish neuropathological subtypes. Neuropsychological assessment protocols developed at University of Cambridge, University of Toronto, and University of Pennsylvania help differentiate syndromes from Alzheimer-related conditions treated at centers such as Mount Sinai, Mayo Clinic, and Brigham and Women's Hospital.

Classification and subtypes

Clinical classification divides syndromes into behavioral variant and language variants including nonfluent/agrammatic and semantic variants, frameworks promoted by international working groups convened at venues like World Health Organization, Alzheimer's Association, and International Parkinson and Movement Disorder Society. Neuropathological subtypes are categorized by protein pathology—tauopathies, TDP-43 proteinopathies, and FUS proteinopathies—described in monographs and atlases produced by academic presses at Oxford University Press, Cambridge University Press, and publishers collaborating with institutions such as Johns Hopkins University Press. Genetic classifications recognize autosomal dominant and sporadic forms identified through sequencing initiatives at 1000 Genomes Project, UK Biobank, and Genetic Epidemiology of Parkinson's Disease Consortium.

Treatment and management

No disease-modifying therapies are established; management focuses on symptomatic pharmacologic and nonpharmacologic approaches delivered by multidisciplinary teams at centers like Addenbrooke's Hospital, Royal Free Hospital, and Bellevue Hospital. Pharmacologic interventions are guided by evidence from clinical trials funded by agencies such as National Institute for Health and Care Research, European Commission, and philanthropic foundations including Bill & Melinda Gates Foundation, while behavioral interventions, speech therapy, and occupational therapy are provided through rehabilitation services at institutions like Guy's and St Thomas' NHS Foundation Trust, Vanderbilt University Medical Center, and Karolinska University Hospital. Advance care planning, caregiver support, and legal counseling often involve resources from advocacy groups such as Alzheimer's Association (United States), Dementia Friendly America, and national health services.

Epidemiology and prognosis

Epidemiologic studies indicate that onset typically occurs between the fifth and seventh decades, making these disorders a leading cause of early-onset dementia in cohorts reported by population studies at Framingham Heart Study, Rotterdam Study, and Danish National Patient Registry. Prevalence and incidence estimates vary across regions surveyed by public health agencies including Centers for Disease Control and Prevention, Public Health England, and World Health Organization. Prognosis depends on subtype, genetic status, and comorbidities with median survival often shorter than in typical late-onset dementias in analyses published by research groups at University of Sydney, Monash University, and University of Melbourne.

Category:Neurodegenerative disorders